Alemtuzumab induction allows better rejection free graft survival incomparison to basiliximab albeit increased post transplant viralinfections. (November 2016) - Siddagangaiah, V.; Sharma, H.; Lal, N.; Rai, J.; Howse, M.; Ridgway, D.; Sharma, A.; Hammad, A.; Mehra, S.